Interpretation 360
Tier 1|
|
|
Variants
Tumor Types
Interpretation
Some mutations in BRCA2 may be associated with sensitivity to PARP inhibitors. The effect of this missense mutation is not entirely clear. Drug: Rucaparib Niraparib Olaparib
Citations
- Carden CP, et al. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 2010;22(5):473-80
- Mateo J, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015;373(18):1697-708
- Liu JF, et al. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol 2014;133(2):362-9
- Swisher EM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18(1):75-87
- Mirza MR, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016;375(22):2154-2164
- Schram AM, et al. Niraparib in Recurrent Ovarian Cancer. N Engl J Med 2017;376(8):801
Last updated: 2018-04-06 15:08:46 UTC